Answers are grounded in this paper and cite their sources.
Review highlights clinical experience with tolvaptan in Japanese congestive heart failure patients, indicating expanded utility beyond conventional hyponatremia management.
Tolvaptan is a vasopressin type 2 receptor antagonist. Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function. Our review of this newly introduced drug is based on our experience in Japan. Clinical Pharmacology & Therapeutics (2013); 94 4, 449–451. doi:10.1038/clpt.2013.147
No takes yet. Share an insight, caveat, or question.
Kinugawa et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: